NLM Digital Collections

Search

Search Constraints

Start Over You searched for: Dates by Range 2000 and later Remove constraint Dates by Range: 2000 and later

Search Results

601. Considerations for design, development, and analytical validation of next generation sequencing (NGS)--based in vitro diagnostics (IVDs) intended to aid in the diagnosis of suspected germline diseases: guidance for stakeholders and Food and Drug Administration staff

602. Use of public human genetic variant databases to support clinical validity for genetic and genomic-based in vitro diagnostics: guidance for stakeholders and Food and Drug Administration staff

604. Q7 good manufacturing practice guidance for active pharmaceutical ingredients: questions and answers

606. Clinical trial imaging endpoint process standards

607. Assessing user fees under the Prescription Drug User Fee Amendments of 2017

608. S3A guidance: note for guidance on toxicokinetics : the assessment of systemic exposure in toxicity studies : focus on microsampling : questions and answers

610. Establishing effectiveness for drugs intended to treat male hypogonadotropic hypogonadism attributed to nonstructural disorders